Eli Lilly (NYSE:LLY) shares rose for seven straight sessions, as the stock ended 1.5% higher at $915.2 on Wednesday. The U.S. pharmaceutical giant gained over 5% in the preceding six sessions.

Below is Validea's guru fundamental report for ELI LILLY AND CO (LLY). Of the 22 guru strategies we follow, LLY rates highest using our P/B Growth Investor model based on the published strategy of ...

Eli Lilly (LLY) and Company announced at plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States.

Eli Lilly will invest tens of billions more dollars in U.S. drug manufacturing in a significant enlargement of plans the Indianapolis company had already described as historic. Lilly, which makes the ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other high growth mega cap stocks. Exactly 5 years ago, the world struggled to deal with a ...

significantly expanding the supply of Zepbound in response to high demand. Price Action: LLY stock is up 1.6% at $896 during the premarket session at last check Tuesday.

President Donald Trump reportedly issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the U.S. or face the possibility of tariffs. What ...

Jane Fonda may be experiencing the honor of a lifetime at this evening’s SAG Awards, but the legendary actor kicked off the night with a rather uncomfortable red carpet interview with Lilly Singh.

TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 class of weight loss/obesity drugs could reach $139B by 2030 ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the pharmaceutical company from preparing for its launch.